BR112023015359A2 - Composto de pirimidopirano - Google Patents
Composto de pirimidopiranoInfo
- Publication number
- BR112023015359A2 BR112023015359A2 BR112023015359A BR112023015359A BR112023015359A2 BR 112023015359 A2 BR112023015359 A2 BR 112023015359A2 BR 112023015359 A BR112023015359 A BR 112023015359A BR 112023015359 A BR112023015359 A BR 112023015359A BR 112023015359 A2 BR112023015359 A2 BR 112023015359A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pyrimidopyrane
- pyrimidopyran
- iii
- represented
- Prior art date
Links
- -1 PYRIMIDOPYRANE COMPOUND Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
composto de pirimidopirano. o presente pedido diz respeito a um composto de pirimidopirano e revela especificamente um composto conforme representado pela fórmula (iii) e um sal farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110139674 | 2021-02-01 | ||
| CN202110258547 | 2021-03-09 | ||
| CN202110706033 | 2021-06-24 | ||
| CN202210070174 | 2022-01-20 | ||
| PCT/CN2022/074390 WO2022161443A1 (zh) | 2021-02-01 | 2022-01-27 | 嘧啶并吡喃类化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023015359A2 true BR112023015359A2 (pt) | 2023-11-14 |
Family
ID=82653023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023015359A BR112023015359A2 (pt) | 2021-02-01 | 2022-01-27 | Composto de pirimidopirano |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4286378A1 (pt) |
| JP (1) | JP2024504831A (pt) |
| KR (1) | KR20230138509A (pt) |
| CN (1) | CN116761799A (pt) |
| AU (1) | AU2022212151A1 (pt) |
| BR (1) | BR112023015359A2 (pt) |
| CA (1) | CA3207058A1 (pt) |
| IL (1) | IL304845A (pt) |
| MX (1) | MX2023009037A (pt) |
| TW (1) | TWI793999B (pt) |
| WO (1) | WO2022161443A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023284881A1 (en) * | 2021-07-16 | 2023-01-19 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds useful as kras g12d inhibitors |
| WO2023138601A1 (zh) * | 2022-01-21 | 2023-07-27 | 南京明德新药研发有限公司 | 桥环取代的杂芳基并吡喃类衍生物及其应用 |
| WO2023198078A1 (zh) * | 2022-04-11 | 2023-10-19 | 杭州英创医药科技有限公司 | 作为kras g12d抑制剂的多环化合物 |
| WO2024064335A1 (en) * | 2022-09-23 | 2024-03-28 | Ikena Oncology, Inc. | Naphthyl-substituted pyranopyrimidinones and related compounds and their use in treating medical conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3024523A1 (en) * | 2016-05-18 | 2017-11-23 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| HUE061599T2 (hu) * | 2017-11-15 | 2023-07-28 | Mirati Therapeutics Inc | KRas G12C inhibotorok |
| AU2019320945C1 (en) * | 2018-08-16 | 2021-09-30 | F. Hoffmann-La Roche Ag | Fused ring compounds |
| CN113396147A (zh) * | 2019-05-31 | 2021-09-14 | 上海翰森生物医药科技有限公司 | 芳香杂环类衍生物调节剂、其制备方法和应用 |
| CN112390788A (zh) * | 2019-08-13 | 2021-02-23 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
-
2022
- 2022-01-27 JP JP2023546247A patent/JP2024504831A/ja active Pending
- 2022-01-27 EP EP22745316.4A patent/EP4286378A1/en active Pending
- 2022-01-27 AU AU2022212151A patent/AU2022212151A1/en active Pending
- 2022-01-27 CN CN202280012164.9A patent/CN116761799A/zh active Pending
- 2022-01-27 BR BR112023015359A patent/BR112023015359A2/pt unknown
- 2022-01-27 MX MX2023009037A patent/MX2023009037A/es unknown
- 2022-01-27 WO PCT/CN2022/074390 patent/WO2022161443A1/zh active Application Filing
- 2022-01-27 KR KR1020237029569A patent/KR20230138509A/ko unknown
- 2022-01-27 CA CA3207058A patent/CA3207058A1/en active Pending
- 2022-01-27 TW TW111103778A patent/TWI793999B/zh active
-
2023
- 2023-07-30 IL IL304845A patent/IL304845A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024504831A (ja) | 2024-02-01 |
| MX2023009037A (es) | 2023-08-10 |
| TWI793999B (zh) | 2023-02-21 |
| KR20230138509A (ko) | 2023-10-05 |
| AU2022212151A1 (en) | 2023-08-17 |
| CA3207058A1 (en) | 2022-08-04 |
| WO2022161443A1 (zh) | 2022-08-04 |
| EP4286378A1 (en) | 2023-12-06 |
| IL304845A (en) | 2023-09-01 |
| TW202233630A (zh) | 2022-09-01 |
| CN116761799A (zh) | 2023-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023015359A2 (pt) | Composto de pirimidopirano | |
| BR112022012585A2 (pt) | Inibidores de formas mutantes de egfr | |
| BR112018002499A2 (pt) | método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica | |
| BR112022018140A2 (pt) | Compostos pirimidoheterocíclicos e aplicação dos mesmos | |
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| MX367618B (es) | Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos. | |
| EA201590913A1 (ru) | АЛКИЛАМИДЗАМЕЩЕННЫЕ ПИРИДИЛЬНЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα | |
| BR112020016020A8 (pt) | Inibidor de atr e aplicação do mesmo | |
| BR112016011755A2 (pt) | derivado de ureia ou sal farmacologicamente aceitável do mesmo | |
| AU2013380573A8 (en) | A process for sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane | |
| EA201490747A1 (ru) | 1-арилкарбонил-4-оксипиперидиновые соединения, полезные для лечения нейродегенеративных заболеваний | |
| BR112020008664A8 (pt) | Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo | |
| BR112014026266A2 (pt) | derivado de quinazolidinadiona | |
| MX2021000348A (es) | 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo. | |
| EA201991253A1 (ru) | Бензодиазолиевые соединения в качестве ингибиторов enac | |
| BR112021022105A2 (pt) | Inibidores de cdk | |
| ECSP24003395A (es) | Sal | |
| MX364400B (es) | Compuestos de tetraciclina. | |
| BR112014026305A2 (pt) | derivado de quinazolidinadiona | |
| MX2022000945A (es) | Composicion para incrementar la expresion de pgc-1alfa. | |
| DOP2014000250A (es) | Nuevos compuestos de pirazol | |
| MY185971A (en) | Pyranodipyridine compound | |
| CO2020003424A2 (es) | Cristal | |
| MX2021007140A (es) | Compuesto para usarse en enfermedades de la retina. | |
| BR112019001447A2 (pt) | método de produção para composto pirazol-amida |